JP2019507763A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507763A5 JP2019507763A5 JP2018545659A JP2018545659A JP2019507763A5 JP 2019507763 A5 JP2019507763 A5 JP 2019507763A5 JP 2018545659 A JP2018545659 A JP 2018545659A JP 2018545659 A JP2018545659 A JP 2018545659A JP 2019507763 A5 JP2019507763 A5 JP 2019507763A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- nucleic acid
- acid molecule
- composition according
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305234.3 | 2016-03-01 | ||
| EP16305234 | 2016-03-01 | ||
| PCT/EP2017/054702 WO2017148976A1 (en) | 2016-03-01 | 2017-03-01 | Treatment of cancer by systemic administration of dbait molecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507763A JP2019507763A (ja) | 2019-03-22 |
| JP2019507763A5 true JP2019507763A5 (enExample) | 2020-03-05 |
| JP6949859B2 JP6949859B2 (ja) | 2021-10-13 |
Family
ID=55588189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545659A Expired - Fee Related JP6949859B2 (ja) | 2016-03-01 | 2017-03-01 | Ｄｂａｉｔ分子の全身投与によるガンの処置 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10821128B2 (enExample) |
| EP (1) | EP3423068A1 (enExample) |
| JP (1) | JP6949859B2 (enExample) |
| KR (2) | KR20220127360A (enExample) |
| CN (1) | CN109069528B (enExample) |
| CA (1) | CA3016355A1 (enExample) |
| WO (1) | WO2017148976A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3461488A1 (en) * | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dbait molecule and a hdac inhibitor for treating cancer |
| US20200407720A1 (en) * | 2018-03-13 | 2020-12-31 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
| IL282838B2 (en) * | 2018-12-21 | 2025-05-01 | Valerio Therapeutics | Conjugated nucleic acid molecules and their uses |
| KR20210142154A (ko) * | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021178295A1 (en) * | 2020-03-03 | 2021-09-10 | University Of Washington | Synthetic agonists of dna-pk and their use |
| TW202210633A (zh) * | 2020-06-05 | 2022-03-16 | 法商昂席歐公司 | 用於治療癌症之dbait分子與kras抑制劑的組合 |
| TW202214857A (zh) | 2020-06-19 | 2022-04-16 | 法商昂席歐公司 | 新型結合核酸分子及其用途 |
| US20240294926A1 (en) | 2021-12-16 | 2024-09-05 | Valerio Therapeutics | New conjugated nucleic acid molecules and their uses |
| WO2024240858A1 (en) * | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1526177A1 (en) | 2003-10-24 | 2005-04-27 | Institut Curie | Nucleic acids useful for triggering tumor cell lethality |
| US7476729B2 (en) * | 2003-10-24 | 2009-01-13 | Institut Curie | Dbait and uses thereof |
| EP1944369A1 (en) * | 2007-01-12 | 2008-07-16 | The Centre National de la Recherche Scientifique | Dbait and its standalone uses thereof |
| US8575123B2 (en) * | 2008-04-11 | 2013-11-05 | Tekmira Pharmaceuticals Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| DK3372248T3 (da) * | 2010-06-22 | 2020-04-06 | Onxeo | Optimeret in vivo leveringssystem med endosomolytiske midler til nukleinsyrekonjugater |
| EP2527440A1 (en) * | 2011-05-27 | 2012-11-28 | Institut Curie | Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia |
-
2017
- 2017-03-01 WO PCT/EP2017/054702 patent/WO2017148976A1/en not_active Ceased
- 2017-03-01 JP JP2018545659A patent/JP6949859B2/ja not_active Expired - Fee Related
- 2017-03-01 CN CN201780014979.XA patent/CN109069528B/zh active Active
- 2017-03-01 US US16/081,045 patent/US10821128B2/en active Active
- 2017-03-01 KR KR1020227030539A patent/KR20220127360A/ko not_active Ceased
- 2017-03-01 KR KR1020187027868A patent/KR102441432B1/ko active Active
- 2017-03-01 EP EP17708463.9A patent/EP3423068A1/en not_active Withdrawn
- 2017-03-01 CA CA3016355A patent/CA3016355A1/en active Pending
-
2020
- 2020-09-30 US US17/038,704 patent/US20210023116A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507763A5 (enExample) | ||
| US11464865B2 (en) | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | |
| US11591596B2 (en) | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | |
| JP6758335B2 (ja) | テロメラーゼ阻害のための改変オリゴヌクレオチド | |
| JP2025111544A (ja) | 核酸の送達のための新規脂質および脂質ナノ粒子製剤 | |
| ES2899043T3 (es) | Novedosos conjugados de oligonucleótidos y su uso | |
| US20160193354A1 (en) | Antisense oligonucleotides with improved pharmacokinetic properties | |
| US9701962B2 (en) | Hydrophobically modified antisense oligonucleotides comprising a ketal group | |
| JP2014516977A5 (enExample) | ||
| ES2755126T3 (es) | Oligonucleótidos antisentido modificados hidrofóbicamente que comprenden una triple cadena alquílica | |
| JP2018534361A5 (enExample) | ||
| CA3163934A1 (en) | Use of lipid in preparation of nucleic acid delivery reagent and related product thereof | |
| George et al. | Advances in nanotechnology-based platforms for survivin-targeted drug discovery | |
| CN106467915B (zh) | 小干扰RNA及其应用和抑制plk1基因表达的方法 | |
| JP2025521209A (ja) | 低分子治療薬の非ウイルス性送達 | |
| Ito et al. | Development of hydrophobic interaction-based DNA supramolecules as efficient delivery carriers of CpG DNA to immune cells | |
| JP5934848B1 (ja) | 局所投与用リポプレックスの新規製造方法及び該リポプレックスを使用する抗腫瘍剤 | |
| US11649457B2 (en) | Methods for treating SARS-CoV-2 infection | |
| US11786545B2 (en) | Compositions and methods for treating SARS-CoV-2 infection | |
| US20240035035A1 (en) | Compositions and methods for treating, ameliorating, and/or preventing viral infections | |
| CN118265791A (zh) | 用于cGAS-STING和STAT3通路调节以对癌症进行免疫治疗性治疗的球形核酸 | |
| CA3195631A1 (en) | Multi-conjugates comprising a mono-substituted homo-bivalent linker | |
| AU2015255202B2 (en) | Novel nucleic acid prodrugs and methods of use thereof | |
| Gao et al. | Hyaluronic Acid-Functionalized PLGA Nanoparticles Loaded with circSNX6 siRNA Overcome Sunitinib Resistance in Renal Cell Carcinoma | |
| US20220175810A1 (en) | Compositions and methods for treating, ameliorating, and/or preventing viral infections |